Larazotide Peptide: Zonulin Antagonist and Celiac Trials

Larazotide is an investigational peptide with an evidence story that is very different from the marketing around most research-market gut peptides. Also known as larazotide acetate, AT-1001 or INN-202, it is an orally administered, gut-restricted peptide that was developed as a tight-junction regulator for celiac disease. It is notable for two reasons: it was the first pharmacologic candidate for celiac disease to reach a Phase 3 trial, and that pivotal trial was halted for futility.

This guide is educational and not medical advice. Larazotide is not an approved medicine and is not available as a prescription product. Nothing here is a protocol, a dose recommendation or an endorsement of unsupervised use.

Larazotide At A Glance

What Larazotide Is

Larazotide acetate is a synthetic peptide eight amino acids long. Its structure is derived from zonula occludens toxin (ZOT), a protein secreted by Vibrio cholerae that loosens the junctions between intestinal cells. Rather than mimicking that loosening effect, larazotide was designed to do the opposite: to help keep the intestinal barrier tight when it would otherwise leak.

Unlike injectable hormone or growth-factor peptides, larazotide is taken by mouth and works inside the gut. Pharmacokinetic studies are important here. In proof-of-concept and later trials, plasma concentrations at therapeutic doses were below the limit of quantification, often cited as under 0.05 ng/mL. In plain terms, the drug essentially stays in the gut lumen and intestinal lining and does not build up meaningful systemic blood levels. That gut-restricted profile is central to both its intended safety and its mechanism.

The compound has changed hands several times. The original investigational new drug application was filed with the FDA by Alba Therapeutics in 2005. Alba's larazotide assets were later licensed to Innovate Biopharmaceuticals in 2016, and Innovate subsequently became 9 Meters Biopharma, the company that ran the Phase 3 program.

Mechanism: Zonulin and Tight Junctions

To understand larazotide, you have to understand the intestinal barrier. The cells lining the gut are sealed together by protein complexes called tight junctions. These junctions act like adjustable gaskets, controlling how much can pass between cells through the paracellular route rather than through the cells themselves.

Zonulin is a signaling protein that, when released, prompts those tight junctions to loosen and increases paracellular permeability. In celiac disease, gluten fragments such as gliadin can trigger zonulin release. The barrier opens slightly, gluten peptides reach the underlying immune tissue, and in genetically susceptible people this drives the inflammatory, autoimmune response that damages the small intestine.

Larazotide acts as a zonulin antagonist and tight-junction regulator. By blocking zonulin signaling and the actin rearrangement that pulls junctions apart, it is intended to limit the gluten-induced increase in permeability. The goal is not to replace the gluten-free diet but to reduce the leak that occurs when small amounts of gluten are inevitably encountered. This is a fundamentally different strategy from peptides that act on the gut in other ways, such as linaclotide, which works through guanylate cyclase-C to affect fluid secretion and motility, or teduglutide, a GLP-2 analog used to promote intestinal absorptive surface in short bowel syndrome.

Clinical Evidence: From Phase 2 Promise To Phase 3 Failure

Larazotide has a relatively long and well-documented clinical history, which is why its trajectory is instructive.

Early proof of concept. A 2007 inpatient, double-blind, placebo-controlled study (Paterson and colleagues) tested single doses of AT-1001 in celiac subjects undergoing a gluten challenge. It established a favorable safety and tolerability signal and explored intestinal permeability using lactulose and mannitol excretion as a marker.

Gluten-challenge trials. Two larger randomized, double-blind studies followed. Leffler and colleagues (2012, American Journal of Gastroenterology) reported that larazotide acetate reduced gluten-induced immune reactivity and symptoms during a gluten challenge and was generally well tolerated. Kelly and colleagues (2013, Alimentary Pharmacology and Therapeutics) studied patients undergoing a gluten challenge and found the 0.5 mg dose performed best on symptom endpoints. A recurring and somewhat counterintuitive theme emerged across these studies: lower doses tended to outperform higher ones, an inverse dose-response pattern.

The Phase 2b symptom trial. The most influential study was Leffler and colleagues (2015, Gastroenterology), a multicenter Phase 2b trial in 342 adults who still had symptoms despite a gluten-free diet. Doses of 0.5 mg, 1 mg and 2 mg three times daily were compared with placebo. Only the lowest dose, 0.5 mg, met the primary endpoint, with significantly fewer symptoms than placebo, while the higher doses did not separate from placebo. Safety was comparable to placebo. This result positioned the 0.5 mg dose as the candidate to advance.

Phase 3 CeDLara and its discontinuation. On the strength of that Phase 2b result, larazotide became the first celiac disease drug to reach Phase 3. The CeDLara trial (ClinicalTrials.gov NCT03569007) was a randomized, double-blind, placebo-controlled study enrolling roughly 525 to 600 adults with persistent symptoms on a gluten-free diet, randomized to 0.25 mg larazotide, 0.5 mg larazotide or placebo. In June 2022, 9 Meters Biopharma announced it was discontinuing the trial. An interim analysis indicated that the number of patients needed to demonstrate a statistically significant difference between larazotide and placebo had grown too large to justify continuing. In other words, the trial was stopped for futility, not because of a safety problem.

That outcome is the headline that any honest summary of larazotide must lead with. Despite encouraging earlier data, the pivotal trial did not support efficacy, and larazotide is not approved for celiac disease or any other indication. Researchers have discussed the broader concept of zonulin inhibition for conditions beyond celiac disease, including inflammatory and autoimmune contexts, but those remain hypotheses rather than proven uses.

Safety Profile

Across its clinical program, larazotide's safety profile was generally reassuring, which makes its failure a story about efficacy rather than harm.

The favorable tolerability does not translate into a recommendation. A peptide that is safe but unproven for benefit, and that failed its pivotal trial, has no established therapeutic role. The honest framing is that larazotide demonstrated an acceptable safety profile but did not demonstrate efficacy at the confirmatory stage.

How To Read Larazotide Claims

Larazotide is sometimes grouped loosely with gut-repair or "leaky gut" peptides such as BPC-157 or KPV. That framing is misleading. Larazotide has a specific, well-characterized mechanism (zonulin antagonism) and a large, transparent clinical record, including a failed Phase 3 trial. Most barrier-repair peptides marketed online have no comparable human evidence. The fact that larazotide reached Phase 3 and still failed should temper any expectation that a related peptide will reliably "heal" the gut.

A few questions help evaluate any larazotide claim. Does the source acknowledge that the Phase 3 CeDLara trial was halted for futility? Does it correctly describe larazotide as oral and gut-restricted rather than a systemic injectable? Does it avoid implying approval or a standard dose? And does it separate mechanism plausibility from proven clinical benefit? For background on how peptide drugs are characterized, see what peptides are and the peptide half-life guide.

Bottom Line

Larazotide acetate is a scientifically interesting peptide: an oral, gut-restricted, eight-amino-acid zonulin antagonist designed to tighten the intestinal barrier and limit gluten-driven permeability in celiac disease. It earned a place in pharmacology history as the first celiac disease drug to reach Phase 3, supported by Phase 2 data in which the low 0.5 mg dose reduced symptoms with placebo-comparable safety.

But the decisive result is the one that matters most. The pivotal Phase 3 CeDLara trial was discontinued for futility in 2022, and larazotide remains investigational and unapproved. It is best understood today as a well-studied mechanism that did not clear the bar of a confirmatory efficacy trial, not as an available treatment. Anyone managing celiac disease should rely on a strict gluten-free diet and qualified medical care rather than on larazotide or peptides marketed with similar barrier-repair language.

References

1. Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007.

2. Leffler DA, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012.

3. Kelly CP, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013.

4. Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015.

5. Khaleghi S, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016.

6. Troisi J, et al. The therapeutic use of the zonulin inhibitor AT-1001 (larazotide) for a variety of acute and chronic inflammatory diseases. Curr Med Chem. 2021.

7. ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms (CeDLara), NCT03569007.